Ampicillin Trihydrate

Urinary Tract Infections, Endocarditis, Whooping Cough + 17 more

Treatment

19 FDA approvals

20 Active Studies for Ampicillin Trihydrate

What is Ampicillin Trihydrate

Ampicillin

The Generic name of this drug

Treatment Summary

Ampicillin is a type of oral antibiotic derived from penicillin. It works against a wide range of bacterial infections.

Ampicillin

is the brand name

Ampicillin Trihydrate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Ampicillin

Ampicillin

1971

270

Approved as Treatment by the FDA

Ampicillin, also called Ampicillin, is approved by the FDA for 19 uses such as Infection caused by eikenella corrodens and Urinary Tract Infection (UTI) .

Infection caused by eikenella corrodens

Urinary Tract Infection (UTI)

Used to treat Bacterial Infections in combination with Sulbactam

Gastrointestinal Tract Infections

Pertussis

disease caused by Salmonella typhi

Recurrent Upper and Lower Respiratory Tract Infections (RTIs)

bacterial skin infections

Bacterial Infections

Used to treat Bacterial Infections in combination with Sulbactam

perinatal group B streptococcus

Salmonella

Shigella

Listeria infection

Disease

Bacterial Infections

Urinary Tract Infections

Respiratory Tract Infections

Communicable Diseases

Listeriosis

Whooping Cough

Effectiveness

How Ampicillin Trihydrate Affects Patients

Ampicillin is an antibiotic used to treat bacterial infections that are usually caused by certain types of bacteria. It is part of the group of antibiotics called penicillin, which can fight both gram-positive and gram-negative bacteria. Ampicillin works by preventing bacteria from building cell walls, which is done by binding to special proteins in the bacteria. It is also resistant to many beta-lactamases, which are enzymes that can destroy certain types of antibiotics.

How Ampicillin Trihydrate works in the body

Ampicillin works by attaching to certain proteins found in bacterial cell walls. This prevents the bacteria from finishing the process of building its cell wall, which ultimately causes the bacteria to break apart and die. It is also believed that Ampicillin may interfere with a compound that stops certain enzymes from breaking down the cell wall.

When to interrupt dosage

The measure of Ampicillin Trihydrate relies upon the determined sickness, including Salmonella, Urinary Tract Infection and perinatal group B streptococcus. The dosage varies as per the mode of delivery (e.g. Injection, powder, for solution - Intramuscular; Intravenous or Injection, powder, for solution) noted in the following table.

Condition

Dosage

Administration

Disease

, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg

, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Capsule; Tablet - Oral, Oral, Capsule - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Oral, Liquid - Intramuscular; Intravenous, Capsule, Liquid, Powder, for solution - Intravenous, Liquid - Oral, Capsule; Tablet, Tablet, Tablet - Oral

Urinary Tract Infections

, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg

, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Capsule; Tablet - Oral, Oral, Capsule - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Oral, Liquid - Intramuscular; Intravenous, Capsule, Liquid, Powder, for solution - Intravenous, Liquid - Oral, Capsule; Tablet, Tablet, Tablet - Oral

Endocarditis

, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg

, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Capsule; Tablet - Oral, Oral, Capsule - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Oral, Liquid - Intramuscular; Intravenous, Capsule, Liquid, Powder, for solution - Intravenous, Liquid - Oral, Capsule; Tablet, Tablet, Tablet - Oral

Shigella

, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg

, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Capsule; Tablet - Oral, Oral, Capsule - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Oral, Liquid - Intramuscular; Intravenous, Capsule, Liquid, Powder, for solution - Intravenous, Liquid - Oral, Capsule; Tablet, Tablet, Tablet - Oral

Respiratory Tract Infections

, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg

, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Capsule; Tablet - Oral, Oral, Capsule - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Oral, Liquid - Intramuscular; Intravenous, Capsule, Liquid, Powder, for solution - Intravenous, Liquid - Oral, Capsule; Tablet, Tablet, Tablet - Oral

Gastrointestinal Tract Infections

, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg

, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Capsule; Tablet - Oral, Oral, Capsule - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Oral, Liquid - Intramuscular; Intravenous, Capsule, Liquid, Powder, for solution - Intravenous, Liquid - Oral, Capsule; Tablet, Tablet, Tablet - Oral

Bacterial Infections

, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg

, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Capsule; Tablet - Oral, Oral, Capsule - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Oral, Liquid - Intramuscular; Intravenous, Capsule, Liquid, Powder, for solution - Intravenous, Liquid - Oral, Capsule; Tablet, Tablet, Tablet - Oral

Bacterial Infections

, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg

, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Capsule; Tablet - Oral, Oral, Capsule - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Oral, Liquid - Intramuscular; Intravenous, Capsule, Liquid, Powder, for solution - Intravenous, Liquid - Oral, Capsule; Tablet, Tablet, Tablet - Oral

Urinary Tract Infections

, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg

, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Capsule; Tablet - Oral, Oral, Capsule - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Oral, Liquid - Intramuscular; Intravenous, Capsule, Liquid, Powder, for solution - Intravenous, Liquid - Oral, Capsule; Tablet, Tablet, Tablet - Oral

Whooping Cough

, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg

, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Capsule; Tablet - Oral, Oral, Capsule - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Oral, Liquid - Intramuscular; Intravenous, Capsule, Liquid, Powder, for solution - Intravenous, Liquid - Oral, Capsule; Tablet, Tablet, Tablet - Oral

Communicable Diseases

, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg

, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Capsule; Tablet - Oral, Oral, Capsule - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Oral, Liquid - Intramuscular; Intravenous, Capsule, Liquid, Powder, for solution - Intravenous, Liquid - Oral, Capsule; Tablet, Tablet, Tablet - Oral

perinatal group B streptococcus

, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg

, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Capsule; Tablet - Oral, Oral, Capsule - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Oral, Liquid - Intramuscular; Intravenous, Capsule, Liquid, Powder, for solution - Intravenous, Liquid - Oral, Capsule; Tablet, Tablet, Tablet - Oral

Salmonella

, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg

, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Capsule; Tablet - Oral, Oral, Capsule - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Oral, Liquid - Intramuscular; Intravenous, Capsule, Liquid, Powder, for solution - Intravenous, Liquid - Oral, Capsule; Tablet, Tablet, Tablet - Oral

Meningitis, Bacterial

, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg

, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Capsule; Tablet - Oral, Oral, Capsule - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Oral, Liquid - Intramuscular; Intravenous, Capsule, Liquid, Powder, for solution - Intravenous, Liquid - Oral, Capsule; Tablet, Tablet, Tablet - Oral

Septicemia

, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg

, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Capsule; Tablet - Oral, Oral, Capsule - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Oral, Liquid - Intramuscular; Intravenous, Capsule, Liquid, Powder, for solution - Intravenous, Liquid - Oral, Capsule; Tablet, Tablet, Tablet - Oral

Listeriosis

, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg

, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Capsule; Tablet - Oral, Oral, Capsule - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Oral, Liquid - Intramuscular; Intravenous, Capsule, Liquid, Powder, for solution - Intravenous, Liquid - Oral, Capsule; Tablet, Tablet, Tablet - Oral

Urinary Tract Infection (UTI)

, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg

, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Capsule; Tablet - Oral, Oral, Capsule - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Oral, Liquid - Intramuscular; Intravenous, Capsule, Liquid, Powder, for solution - Intravenous, Liquid - Oral, Capsule; Tablet, Tablet, Tablet - Oral

Cesarean Section

, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg

, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Capsule; Tablet - Oral, Oral, Capsule - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Oral, Liquid - Intramuscular; Intravenous, Capsule, Liquid, Powder, for solution - Intravenous, Liquid - Oral, Capsule; Tablet, Tablet, Tablet - Oral

Hysterectomy, Vaginal

, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg

, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Capsule; Tablet - Oral, Oral, Capsule - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Oral, Liquid - Intramuscular; Intravenous, Capsule, Liquid, Powder, for solution - Intravenous, Liquid - Oral, Capsule; Tablet, Tablet, Tablet - Oral

Infection

, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg

, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Capsule; Tablet - Oral, Oral, Capsule - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Oral, Liquid - Intramuscular; Intravenous, Capsule, Liquid, Powder, for solution - Intravenous, Liquid - Oral, Capsule; Tablet, Tablet, Tablet - Oral

Warnings

Ampicillin Trihydrate has one contraindication, so it should not be ingested for the conditions presented in the following table.

Ampicillin Trihydrate Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Ampicillin may interact with Pulse Frequency

There are 20 known major drug interactions with Ampicillin Trihydrate.

Common Ampicillin Trihydrate Drug Interactions

Drug Name

Risk Level

Description

Vibrio cholerae CVD 103-HgR strain live antigen

Major

The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Ampicillin.

Abacavir

Minor

Ampicillin may decrease the excretion rate of Abacavir which could result in a higher serum level.

Aclidinium

Minor

Ampicillin may decrease the excretion rate of Aclidinium which could result in a higher serum level.

Acrivastine

Minor

Ampicillin may decrease the excretion rate of Acrivastine which could result in a higher serum level.

Albutrepenonacog alfa

Minor

Ampicillin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.

Ampicillin Trihydrate Novel Uses: Which Conditions Have a Clinical Trial Featuring Ampicillin Trihydrate?

67 active studies are currently being conducted to investigate the potential of Ampicillin Trihydrate in combating Urinary Tract Infection, Communicable Diseases, and Endocarditis.

Condition

Clinical Trials

Trial Phases

Infection

11 Actively Recruiting

Not Applicable, Phase 1, Phase 4, Phase 3

Meningitis, Bacterial

0 Actively Recruiting

Endocarditis

1 Actively Recruiting

Not Applicable

Shigella

1 Actively Recruiting

Phase 2

Bacterial Infections

0 Actively Recruiting

Cesarean Section

5 Actively Recruiting

Not Applicable, Phase 4

Septicemia

1 Actively Recruiting

Not Applicable

Urinary Tract Infections

0 Actively Recruiting

Whooping Cough

0 Actively Recruiting

Urinary Tract Infection (UTI)

5 Actively Recruiting

Phase 1, Phase 3, Phase 4, Not Applicable

Communicable Diseases

0 Actively Recruiting

Listeriosis

0 Actively Recruiting

Urinary Tract Infections

15 Actively Recruiting

Not Applicable, Phase 4, Early Phase 1, Phase 3

Disease

0 Actively Recruiting

Gastrointestinal Tract Infections

0 Actively Recruiting

Hysterectomy, Vaginal

0 Actively Recruiting

Respiratory Tract Infections

2 Actively Recruiting

Phase 3, Not Applicable

Bacterial Infections

0 Actively Recruiting

Salmonella

0 Actively Recruiting

perinatal group B streptococcus

0 Actively Recruiting

Patient Q&A Section about ampicillin trihydrate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is amoxicillin trihydrate used to treat?

"It is used to treat bacterial infections, such as chest infections (including pneumonia) and dental abscesses. It can also be used together with other antibiotics and medicines to treat stomach ulcers. It's often prescribed for children, to treat ear infections and chest infections. Eradacil can also be used to treat other conditions as determined by your doctor."

Answered by AI

What is the meaning of ampicillin trihydrate?

"Ampicillin Trihydrate prevents bacteria from making new cell walls, which eventually leads to the death of the bacteria. This is achieved by binding to proteins that are essential for cell wall synthesis."

Answered by AI

What is ampicillin trihydrate used for?

"It will not work for viral infections (such as common cold, flu).

Ampicillin is used to treat a wide variety of bacterial infections. It is a penicillin-type antibiotic that works by stopping the growth of bacteria. This antibiotic only treats bacterial infections and will not work for viral infections such as the common cold or flu."

Answered by AI

Is ampicillin a strong antibiotic?

"Ampicillin can be an effective antibiotic against a variety of bacteria but is not as commonly prescribed as it used to be because resistance can occur when it is used alone."

Answered by AI

Clinical Trials for Ampicillin Trihydrate

Image of Seattle Children's Hospital in Seattle, United States.

Follow-Up Strategies for Children With Medical Complexity

1 - 16
All Sexes
Seattle, WA

Children with medical complexity often receive a recommendation to see an outpatient clinician soon after leaving the hospital. It is uncertain whether every child needs this routine visit or whether follow-up can be guided by the family's concerns and the child's recovery. AFTERCARE is a multicenter pilot randomized trial comparing these two follow-up recommendations for children hospitalized with an acute infection. Families will be assigned by chance to receive either a recommendation to arrange follow-up with their usual outpatient clinician within seven days or a recommendation to seek follow-up if the child is not improving as expected or new concerns arise. Families in both groups may seek medical care whenever needed. The study will assess recruitment, follow-up data collection, delivery of the recommendations and acceptability. Caregiver surveys and medical record review will also describe outpatient visits and hospital returns. This pilot will inform the design of a larger trial, and is not designed to establish that the strategies are equally safe or effective.

Waitlist Available
Has No Placebo

Seattle Children's Hospital

Nassr Nama, MD, MSc

Image of MedStar National Rehabilitation Hospital in Washington D.C., United States.

Rapid UTI Diagnostics for Urinary Tract Infection

18+
All Sexes
Washington D.C., United States

Patients who seek care through MedStar National Rehab Hospital's clinic believing they have a UTI will be enrolled in this trial. They will be pre-screened after consent according to a standard-of-care clinical symptom measure called the USQNB. If determined by this measure to be at high or moderate likelihood of having a UTI, they will be assigned to the presumed UTI arm and instructed to come to the clinic to provide a urine sample and undergo standard diagnostic testing to determine if a UTI is present. Those not assigned to the presumed UTI arm at this phase are assigned to the presumed no UTI arm and do not present to the clinic. These tests include a repeated questionnaire about the UTI symptoms they are experiencing and collection of a urine sample from a freshly changed indwelling catheter for standard clinical urinalysis testing and culture. Based upon the clinical guideline-informed results of these standard clinical tests, patients will be assigned into one of two potential arms (suspected UTI or suspected non-UTI) based on whether or not they are diagnosed with UTI at that visit. Arm 1 (presumed UTI) participants will have a second urine sample collected at the time of the visit from the used indwelling catheter bag in addition to the freshly changed catheter sample, and both will be divided into three portions: one for repeat clinical tests and culture, one for assessment using the experimental Jiddu device, and one to be stored for potential future studies. The study doctor will then determine antibiotic choice according to standard clinical decision making and record, but not prescribe, that choice. Once results are obtained from the samples sent for experimental analysis, the study doctor will use those results in addition to their best clinical judgement and all standard available clinical evidence to choose the antibiotic treatment. Arm 1 participants will then complete urine symptom surveys at day 3 and 7 during antibiotic use to determine effectiveness of antibiotics prescribed. In the event of standard urine culture results differing from the Jiddu-produced pooled AST values rescue antibiotic consisting of the antibiotic choice based on best clinical judgement using this newly available evidence will be used to ensure safety and this survey clock will restart and include a USQNB on day 10. Arm 2 participants will repeat the urinary symptoms questionnaire 3 and 7 days after their initial completion to see if their symptoms have changed and would allow them to qualify. If they remain unqualified at 7 days, they will be instructed to fill out another survey the next time they think they have a UTI. This process will repeat until they either qualify to become an Arm 1 participant or 6 months have passed since they first consented.

Waitlist Available
Has No Placebo

MedStar National Rehabilitation Hospital

Ana Valeria Aguirre Guemez, MD

Image of Montefiore Medical Center in The Bronx, United States.

Support Pillow for Spine Surgery Recovery

18+
All Sexes
The Bronx, NY

The present study investigates the feasibility of a support pillow for use after spinal surgical procedures, and more particularly, to protect the midline region of the back following spinal surgery. Existing cushioning pillows do not accommodate the anatomy of the human back nor the requirements of isolating a vertical spinal incision. For example, donut-style or ring-shaped pillows are designed for entirely different purposes, such as hemorrhoidal relief, and cannot provide the desired spinal relief. As a result, there is no suitable, dedicated support structure that allows a patient to rest on their back while eliminating pressure on the surgical site. Accordingly, there is a need for a device that permits postoperative spinal surgery patients to sit or lie in a supine or reclined position without the surgical incision contacting or being compressed by any supporting surface.

Recruiting
Has No Placebo

Montefiore Medical Center

Ananth Eleswarapu, MD

Image of Riverside University Health System Medical Center in Moreno Valley, United States.

Steri-Strips for Cesarean Section Incisions

18+
Female
Moreno Valley, CA

This study is evaluating whether Steri-Strips® provide additional benefits when used after cesarean section (C-section) surgery. Steri-Strips are adhesive strips that are commonly placed over a surgical incision to provide support while the wound heals. At our hospital, Steri-Strips are routinely used after C-sections in addition to standard wound closure techniques, although they are not considered part of the standard recommended closure method. Researchers want to determine whether adding Steri-Strips actually reduces wound complications such as infection, fluid collection under the skin, or reopening of the incision. Previous studies have shown mixed results, with some suggesting little difference in wound healing outcomes while others reported differences in scar appearance. Steri-Strips may also increase costs, add time to the surgery, and occasionally cause skin irritation or allergic reactions. Participants in this study will be randomly assigned to one of two groups. One group will receive standard cesarean wound closure with Steri-Strips, while the other group will receive standard wound closure without Steri-Strips. Researchers will compare wound healing, complications, patient outcomes, and costs between the two groups. The goal of this study is to determine whether Steri-Strips improve recovery after cesarean delivery and whether their routine use is beneficial and cost-effective. The findings may help guide future recommendations for cesarean wound care and improve outcomes for patients undergoing C-section delivery.

Recruiting
Has No Placebo

Riverside University Health System Medical Center

Have you considered Ampicillin Trihydrate clinical trials?

We made a collection of clinical trials featuring Ampicillin Trihydrate, we think they might fit your search criteria.
Go to Trials
Image of The Ottawa Hospital in Ottawa, Canada.

Naproxen for Cellulitis

18+
All Sexes
Ottawa, Canada

Cellulitis is a painful bacterial skin infection commonly seen in Canadian emergency departments. Cellulitis has a negative impact on patients' quality of life and productivity. While this is a bacterial infection, there is evidence inflammation also contributes to the disabling symptoms of pain, redness and swelling. Some studies have suggested that a nonsteroidal anti-inflammatory drug (NSAID) such as naproxen in addition to antibiotics may control inflammation and speed recovery. However, these studies have had too few patients to tell if there is a true benefit. The investigators are proposing a randomized controlled trial of patients with cellulitis to compare oral naproxen (500 mg twice daily) plus oral antibiotics versus placebo plus oral antibiotics. The investigators will compare the proportion of patients who have an early clinical response (reduction in area of redness ≥20% at 72 hours), cure, treatment failure, adverse events, and hospital admission. If naproxen proves to be superior to placebo, this simple, low-cost intervention will speed time to recovery with less pain for patients, and may potentially reduce treatment failure and time missed from activities. The results of this trial will help inform future cellulitis treatment guidelines.

Phase 3
Waitlist Available

The Ottawa Hospital

Krishan Yadav, MD, MSc

Image of Ohio University in Athens, United States.

Virtual Reality for Medical Training

18+
All Sexes
Athens, OH

As the U.S. population ages, future physicians must be prepared to care for older adults with multiple health conditions and complex needs. This study will test whether cinematic virtual reality (VR)-an immersive, interactive learning tool-is more effective than traditional lectures in helping medical students learn about geriatric care. Students who complete the VR training will experience realistic patient scenarios that show what can go wrong in medical care and learn how to apply osteopathic principles to improve outcomes. Researchers will compare students' performance on a clinical skills assessment and explore their experiences with the VR training. The goal is to determine whether cinematic virtual reality can better prepare students for residency and improve their ability to provide compassionate, high-quality care for older adults.

Recruiting
Has No Placebo

Ohio University

Elizabeth A Beverly, PhD

Have you considered Ampicillin Trihydrate clinical trials?

We made a collection of clinical trials featuring Ampicillin Trihydrate, we think they might fit your search criteria.
Go to Trials
Image of University of Washington Medical Center in Seattle, United States.

Copper Supplementation for Liver Cirrhosis

18+
All Sexes
Seattle, WA

End stage liver disease or cirrhosis is a major cause of mortality in the United States and the world. Other than targeting the underlying cause, such as alcohol cessation and antiviral therapy, very few medical treatments can change the natural history of cirrhosis. Malnutrition is one of the few potentially modifiable factors that have been associated with cirrhosis severity and poor prognosis. The transition metal copper (Cu) is an essential trace metal that must be acquired from diet. Its metabolism is primarily regulated by the liver in its role as a master regulator of nutrients. In 2019, the investigators reported that Cu deficiency defined by below normal serum or liver concentrations occurred in a wide range of liver disorders and was associated with a severe disease phenotype. Improvement in liver function was observed in 2 of the 3 patients who received Cu supplementation. In 2023, the investigators conducted a longitudinal cohort study utilizing clinical, serum and liver explant tissue data from 183 cirrhosis patients. The investigators showed that Cu deficiency was associated with 2-fold higher infection rate and a more than 3-fold increase in the risk of death compared to patients with normal Cu status. These preliminary findings and the well-established importance of Cu in human health prompted the investigators to design the current pilot randomized, placebo-controlled, crossover trial to determine the effect of Cu supplementation on Cu dependent biochemical changes, patient safety and patient reported outcomes in cirrhosis.

Recruiting
Has No Placebo

University of Washington Medical Center

Lei Yu, MD

Image of Hospital of the University of Pennsylvania in Philadelphia, United States.

Early General Anesthesia for PTSD During Cesarean Section

18+
Female
Philadelphia, PA

Some patients who undergo cesarean section under spinal or epidural anesthesia can experience severe pain. Some patients who experience this kind of pain can experience symptoms of post-traumatic stress disorder (PTSD) after pregnancy. Currently, the two main options for treating this pain are general anesthesia (full medically induced unconsciousness) and using intravenous medications to reduce the pain and decrease anxiety. The EAGLET-CS Pilot is a pilot randomized trial that will test the feasibility of comparing the impact of these two options for preventing PTSD in a rigorous way for those patients who experience pain during their cesarean section after the baby is out.

Recruiting
Has No Placebo

Hospital of the University of Pennsylvania

Image of Children's of Alabama in Birmingham, United States.

Antibiotic Duration for Infections in Children

60 days - 17 years
All Sexes
Birmingham, AL

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Phase 4
Waitlist Available

Children's of Alabama (+9 Sites)

Sunitha V Kaiser, MD, MSc

Have you considered Ampicillin Trihydrate clinical trials?

We made a collection of clinical trials featuring Ampicillin Trihydrate, we think they might fit your search criteria.
Go to Trials